Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Three months ended December 31, 2013 (fiscal 2014 first quarter). Financial statements are unaudited; amounts below are in U.S. dollars.
Business context
Enanta is a research and development-focused biotechnology company with no approved products and no product-sales revenue. Its programs target hepatitis C virus (HCV) and drug-resistant bacteria. AbbVie leads development and commercialization of Enanta’s protease inhibitors, including ABT-450; Novartis leads development of its NS5A inhibitor EDP-239. Enanta funds its independent HCV cyclophilin and nucleotide-polymerase programs, while NIAID supports development of the Bicyclolide antibiotic EDP-788.
Financial performance and position
| Metric | Q1 FY2014 | Q1 FY2013 |
|---|---|---|
| Revenue | $0.9 million | $27.9 million |
| Research and development expense | $4.3 million | $4.8 million |
| General and administrative expense | $2.1 million | $1.2 million |
| Operating income (loss) | $(5.5) million | $21.9 million |
| Net income (loss) | $(5.4) million | $22.0 million |
| Net income (loss) per share, basic | $(0.30) | $1.61 |
| Net cash from (used in) operations | $(5.9) million | $9.0 million |
Revenue in the current quarter was entirely from NIAID contract work. The prior-year quarter included $15.0 million in an AbbVie milestone and $11.0 million in a Novartis milestone, as well as NIAID revenue. No gross margin or product margin is presented; the company had no product sales.
At December 31, 2013, cash and cash equivalents were $4.4 million, short-term marketable securities were $87.5 million and long-term marketable securities were $14.3 million. Management reported total cash, cash equivalents and investments of $106.2 million. Total assets were $110.2 million, current liabilities $2.6 million, and total liabilities $4.6 million. The company reported no debt outstanding. Operating cash use was partly offset by $1.3 million of investing cash inflow and $0.1 million of financing cash inflow. Cash and cash equivalents declined $4.4 million during the quarter.
Material changes versus the prior comparable period
- Revenue fell $27.0 million, primarily because neither collaboration generated a milestone in the current quarter; the prior-year period had $26.0 million of AbbVie and Novartis milestones.
- The company moved from net income of $22.0 million to a net loss of $5.4 million, and operating cash flow changed from $9.0 million provided to $5.9 million used.
- R&D expense decreased $0.5 million, mainly reflecting lower EDP-788 preclinical and NS5A research spending; Novartis-funded research had ended in August 2013. G&A expense rose $0.9 million, largely due to public-company insurance, accounting and legal costs.
- Compared with September 30, 2013, total cash and marketable securities decreased from approximately $112.2 million to $106.2 million, while total liabilities declined from $6.5 million to $4.6 million.
Outlook, commentary and risks
- Management said existing cash, cash equivalents and marketable securities were expected to fund anticipated requirements for at least 24 months. This is a forward-looking estimate and actual cash needs may differ.
- For fiscal 2014, Enanta expected up to $30.0 million of expense for its own existing R&D programs, excluding collaborator spending. It expected R&D and G&A costs to rise as programs advance and operations expand.
- AbbVie had reported top-line results from six Phase 3 trials of an ABT-450-containing regimen and expected to file an NDA in early Q2 2014, with a 2014 commercial launch anticipated. Elsewhere, Enanta stated its estimate that it would likely be 2015 before an NDA for a collaborator’s candidate could be approved. These are different milestones and timing statements; verify subsequent developments.
- Enanta’s future revenue depends substantially on collaborator execution, regulatory outcomes and milestone timing; it has no product royalties to date. AbbVie and Novartis control key partnered-program development decisions and may terminate their agreements under specified terms.
- NIAID had paid or committed approximately $23.5 million of potential contract funding, with further funding dependent on options and appropriations. The filing cites possible government funding reductions and contract audit or termination risks.
- Commitments include an office and laboratory lease through September 2018 and intellectual-property license payments and maintenance fees. No threatened or pending litigation was reported. The company reported disclosure controls effective and no material change in internal control over financial reporting.
Important facts for investors to verify
- Progress, regulatory filing and approval timing for AbbVie’s ABT-450 regimen, and any resulting milestone or royalty revenue.
- Novartis’s continued development of EDP-239 and the status of potential clinical milestones.
- Whether NIAID exercises further funding options and whether contract funding remains available on the disclosed terms.
- Actual R&D spending, operating cash burn and investment balances relative to management’s 24-month runway estimate.
- The timing and expense impact of performance-based stock options; the filing says certain targets were achieved in fiscal Q2 2014 and compensation expense would be recorded then.